Rocket Pharmaceuticals reports no safety issues in first 3 RP-A501 patients

August 3, 2026 7:00 AM

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) reported that the first three patients treated under a modified Phase 2 protocol for its ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found